SCHEMBL4872595

SCHEMBL4872595

CC(C)C[C@H](NC(=O)c1cccc(OCc2ccccc2)c1)C(=O)Cn1c(-c2ccccc2)noc1=O

nearest known ligand 0.51

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
GPR132 Q9UNW8 13/20 0.51
CTSK P43235 1/20 0.50
KMT2A Q03164 1/20 0.46
CMKLR2 P46091 1/20 0.45
CMKLR1 Q99788 1/20 0.45
TSHR P16473 1/20 0.45
MAPT P10636 1/20 0.45
SMPD1 P17405 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4870124 0.95 GPR132 (0.47) GPR132CTSKKMT2ACMKLR2CMKLR1
SCHEMBL4871196 0.92 GPR132 (0.48) GPR132CTSKCMKLR2CMKLR1MAPT
SCHEMBL4864784 0.91 KMT2A (0.50) GPR132CTSKKMT2ATSHR
SCHEMBL4870638 0.86 CTSS (0.47) GPR132CTSKKMT2ATSHR
SCHEMBL4867468 0.86 KMT2A (0.57) CTSKKMT2ATSHRMAPT
SCHEMBL4871055 0.84 CTSK (0.46) GPR132CTSKKMT2A
SCHEMBL4867859 0.81 KMT2A (0.52) CTSKKMT2ATSHRMAPT
SCHEMBL4863630 0.81 CTSK (0.45) CTSKKMT2ATSHRMAPT
SCHEMBL14158092 0.81 CTSK (0.53) CTSK
SCHEMBL4867898 0.80 GPR132 (0.54) GPR132CTSKKMT2ACMKLR2CMKLR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7390804-B2 N-containing five-membered ring compounds and pharmaceutical agents comprising the same as active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-06-24 US claimed
US-7390804-B2 N-containing five-membered ring compounds and pharmaceutical agents comprising the same as active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-06-24 US disclosed
US-7390804-B2 N-containing five-membered ring compounds and pharmaceutical agents comprising the same as active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-06-24 US disclosed
US-7390804-B2 N-containing five-membered ring compounds and pharmaceutical agents comprising the same as active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-06-24 US disclosed
US-20050164954-A1 N-containing five-membered ring compounds and pharmaceutical agents comprising the same as active ingredient ONO PHARMACEUTICAL CO., LTD. 2005-07-28 US disclosed
US-6900207-B2 N-containing five-membered ring compounds and pharmaceutical agents comprising the same as active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-31 US disclosed
US-20030153508-A1 Nitrogen-containing 5-membered cyclic compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2003-08-14 US disclosed
EP-1254901-A1 NITROGEN-CONTAINING 5-MEMBERED CYCLIC COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2002-11-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050164954-A1 N-containing five-membered ring compounds and pharmaceutical agents comprising the same as active ingredient ACIN1, CASP7, CASP10 GPR132 623/4885CTSK 138/4885KMT2A 4568/4885
US-20030153508-A1 Nitrogen-containing 5-membered cyclic compounds and drugs containing these compounds as the active ingredient ACIN1, CASP7, CASP10 GPR132 942/4885CTSK 396/4885KMT2A 4457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.